Literature DB >> 28405772

Incidence and Prognostic Value of Metastases to "Posterior" and Para-aortic Lymph Nodes in Resectable Gastric Cancer.

Daniele Marrelli1, Francesco Ferrara2, Simone Giacopuzzi3, Paolo Morgagni4, Alberto Di Leo5, Lorenzo De Franco2, Corrado Pedrazzani6, Luca Saragoni7, Giovanni De Manzoni3, Franco Roviello2.   

Abstract

BACKGROUND: The purpose of this retrospective study was to evaluate the incidence and prognostic value of metastases to "posterior" (8p, 12b/p, 13) and para-aortic lymph nodes in a large cohort of Western patients submitted to D2 plus lymphadenectomy.
METHODS: Removal of "posterior" nodes was performed in 743 patients, and para-aortic lymphadenectomy in a subgroup of 390 patients. After lymph node mapping and retrieval on the fresh specimen, a median number of 41 total lymph nodes were analyzed. The median follow-up period was 37 months for the entire series and 68 months for survivors.
RESULTS: Of 743 included patients, 23 (3.1%) had metastases in station 8p, 12 (1.6%) in station 12b/p, and 19 (2.6%) in station 13. On the whole, 47 of 743 patients (6.3%) had positive "posterior" nodes. Para-aortic metastases were present in 42 of 390 patients (10.8%). Metastases to "posterior" stations were significantly related to depth of invasion, number of positive nodes, and surgical radicality. Distal tumors showed higher trend to metastasize to "posterior" nodes than upper third, whereas for para-aortic metastases it was the reverse. 5-year survival in patients with positivity to "posterior" nodes was 17%, with no significant difference according to 8p, 12b/p, and 13 stations; long-term outcome was overlapping to pN3b stage. 5-year survival in para-aortic positive cases was 11%, and a trend to better outcome was observed in proximal tumors.
CONCLUSIONS: Although metastases to "posterior" and para-aortic nodes are expression of an advanced nodal stage, not negligible survival rates are observed in subgroups of patients.

Entities:  

Mesh:

Year:  2017        PMID: 28405772     DOI: 10.1245/s10434-017-5857-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Clinical impact of molecular classifications in gastric cancer.

Authors:  Daniele Marrelli; Karol Polom; Alessandro Neri; Franco Roviello
Journal:  Updates Surg       Date:  2018-05-23

Review 2.  Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives.

Authors:  Valentina Mengardo; Maria Bencivenga; Jacopo Weindelmayer; Michele Pavarana; Simone Giacopuzzi; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2018-05-30

3.  Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.

Authors:  Maria Antonietta Mazzei; Giulio Bagnacci; Francesco Gentili; Andrea Nigri; Veronica Pelini; Carla Vindigni; Francesco Giuseppe Mazzei; Gian Luca Baiocchi; Frida Pittiani; Paolo Morgagni; Enrico Petrella; Gianni Mura; Beatrice Verdelli; Maria Bencivenga; Simone Giacopuzzi; Daniele Marrelli; Franco Roviello; Luca Volterrani
Journal:  Gastroenterol Res Pract       Date:  2018-03-15       Impact factor: 2.260

4.  Evaluation of D2-plus radical resection for gastric cancer with pyloric invasion.

Authors:  Zhi-Yuan Xu; Can Hu; Shangqi Chen; Yi-An Du; Ling Huang; Peng-Fei Yu; Li-Jing Wang; Xiang-Dong Cheng
Journal:  BMC Surg       Date:  2019-11-20       Impact factor: 2.102

Review 5.  Current status of extended 'D2 plus' lymphadenectomy in advanced gastric cancer.

Authors:  Jing-Quan Li; Donglei He; Yue-Xiang Liang
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

6.  Prognostic impact of D2-plus lymphadenectomy and optimal extent of lymphadenectomy in advanced gastric antral carcinoma: Propensity score matching analysis.

Authors:  Weilin Sun; Jingyu Deng; Nannan Zhang; Huifang Liu; Jinyuan Liu; Pengfei Gu; Yingxin Du; Zizhen Wu; Wenting He; Pengliang Wang; Han Liang
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.